Humacyte Says The FDA Will Require Additional Time To Complete Its Review Of The BLA For ATEV In The Treatment Of Vascular Trauma
Portfolio Pulse from Benzinga Newsdesk
Humacyte announced that the FDA will require additional time to complete its review of the Biologics License Application (BLA) for ATEV in the treatment of vascular trauma.
August 09, 2024 | 8:09 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Humacyte announced that the FDA will need more time to review its BLA for ATEV, a treatment for vascular trauma. This delay could impact the company's timeline for bringing the product to market.
The delay in FDA review could postpone the approval and market entry of ATEV, potentially affecting Humacyte's revenue projections and investor sentiment in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100